Dosimetry-Based Consideration on Remission and Relapse after Therapy with 223Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report-Reference-Cited by-同舟云学术

Dosimetry-Based Consideration on Remission and Relapse after Therapy with 223Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report

Published:2018-02-27 Issue:1 Volume:8 Page:18
ISSN:2075-4418
Container-title:Diagnostics
language:en
Short-container-title:Diagnostics

Author:

Mangano Anna,Pacilio Massimiliano,Ialongo Pasquale,Semprebene Alessandro,Ventroni Guido,Mango Lucio

Publisher

MDPI AG

Subject

Clinical Biochemistry

Link

http://www.mdpi.com/2075-4418/8/1/18/pdf

Reference30 articles.

1. Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity

2. Cancer Pain Relief: With a Guide to Opioid Availability,1996

3. Bone-Seeking Radionuclides for Therapy;Lewington;J. Nucl. Med.,2005

4. The palliative management of skeletal metastases in prostate cancer: Use of bone-seeking radionuclides and bisphosphonates

5. Improving the dose–myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in the development of radiopharmaceuticals for nuclear medicine applications in the treatment of bone metastases;Nuclear Medicine and Biology;2024-03

2. Radium-223 and Actinium-225 α-Emitter Radiopharmaceuticals in Treatment of Metastatic Castration-Resistant Prostate Cancer;Radiopharmaceuticals - Current Research for Better Diagnosis and Therapy;2022-06-15

3. Calculation of radium-223 and actinium-225 α-emitter radiopharmaceuticals dose rates in treatment of metastatic castration-resistant prostate cancer;Journal of Cancer Research and Therapeutics;2021

4. Dispersal Rate of Radon-219 from Aqueous Radium-223 Solution Containing Sodium Chloride/Citrate;Radiation Safety Management;2020

5. The homogeneous and heterogeneous risk factors for the morbidity and prognosis of bone metastasis in patients with prostate cancer;Cancer Management and Research;2018-06